C. DeRyke

发表

Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards—SMART United States 2017–2019

K. Kazmierczak, M. Motyl, D. Sahm, 2021, Open forum infectious diseases.

Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia.

M. Rybak, T. Lodise, P. McKinnon, 2005, Chest.

Pharmacodynamic Target Attainment of Six β‐Lactams and Two Fluoroquinolones Against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella Species Collected from United States Intensive Care Units in 2004

D. Nicolau, J. Kuti, C. DeRyke, 2007, Pharmacotherapy.

Performance of a vancomycin dosage regimen developed for obese patients.

D. Alexander, Laura H. Waite, C. DeRyke, 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Activity of Ceftolozane/Tazobactam Against Clinical Isolates of Pseudomonas aeruginosa from Patients in the Middle East and Africa - SMART 2017-2020.

M. Motyl, D. Sahm, K. Young, 2022, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Changes in Pharmacodynamic Target Attainment for Antimicrobials Over a 2-Year Period: Results of the 2004 OPTAMA Program in North America

D. Nicolau, J. Kuti, C. DeRyke, 2007 .

Serum Bactericidal Activities of High-Dose Daptomycin with and without Coadministration of Gentamicin against Isolates of Staphylococcus aureus and Enterococcus species

Bo Zhang, Christina A. Sutherland, D. Nicolau, 2006, Antimicrobial Agents and Chemotherapy.

Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.

D. Nicolau, J. Kuti, C. DeRyke, 2007, Diagnostic microbiology and infectious disease.

Response to Surawicz et al.

S. Gorbach, P. Sears, C. DeRyke, 2014, The American Journal of Gastroenterology.

Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study

A. Srinivasan, D. Depestel, J. Murray, 2018, Open forum infectious diseases.

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020.

M. Motyl, J. Karlowsky, D. Sahm, 2023, Journal of medical microbiology.

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018–20

M. Motyl, J. Karlowsky, D. Sahm, 2022, JAC-antimicrobial resistance.

Optimising Dosing Strategies of Antibacterials Utilising Pharmacodynamic Principles

Su Young Lee, D. Nicolau, S. Y. Lee, 2012, Drugs.

Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.

D. Nicolau, J. Kuti, A. Dana, 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Daptomycin non-susceptible Staphylococcus aureus at a US medical centre.

M. Wallace, R. Goering, C. DeRyke, 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model

D. Nicolau, H. Fan, M. Banevicius, 2007, Antimicrobial Agents and Chemotherapy.

Over-treatment of carbapenemase-producing Enterobacteriaceae

M. Wallace, B. Sieger, C. DeRyke, 2012, Scandinavian journal of infectious diseases.

Is all free time above the minimum inhibitory concentration the same: implications for beta-lactam in vivo modelling.

D. Nicolau, C. DeRyke, 2007, International journal of antimicrobial agents.

A Combination Antibiogram Evaluation for Pseudomonas aeruginosa in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals

A. Srinivasan, L. Puzniak, S. Merchant, 2019, Antimicrobial Agents and Chemotherapy.

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020

M. Motyl, D. Sahm, S. Hawser, 2023, European Journal of Clinical Microbiology & Infectious Diseases.

parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.

G. Doern, D. Nicolau, Xiaoli Du, 2007, International journal of antimicrobial agents.

Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.

D. Nicolau, Xiaoli Du, C. DeRyke, 2006, The Journal of antimicrobial chemotherapy.

Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient

D. Nicolau, D. Maglio, C. DeRyke, 2005, Expert opinion on pharmacotherapy.

Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance

M. Rizk, D. Nicolau, J. Roberts, 2023, JAC-antimicrobial resistance.

In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020

D. Hilbert, M. Motyl, J. Karlowsky, 2022, Antimicrobial agents and chemotherapy.

Antimicrobial stewardship and antibiograms: importance of moving beyond traditional antibiograms

M. Motyl, K. Bauer, D. Depestel, 2021, Therapeutic advances in infectious disease.

Ceftolozane-Tazobactam Activity Against Clinical Isolates of Pseudomonas aeruginosa from ICU Patients with Pneumonia: United States, 2015-2018.

M. Pfaller, D. Shortridge, H. Sader, 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration

D. Alexander, C. DeRyke, 2009 .

Colistin Dosing and Nephrotoxicity in a Large Community Teaching Hospital

N. Uddin, M. Wallace, Amanda J. Crawford, 2010, Antimicrobial Agents and Chemotherapy.

1450. Frequency of Carbapenem-resistant Pseudomonas aeruginosa Among Respiratory Pathogens Impacts First-Line Beta-Lactam Susceptibility: Potential Role for Ceftolozane/Tazobactam (C/T) and/or Imipenem/Relebactam (I/R)

M. Motyl, D. Depestel, K. Klinker, 2020, Open Forum Infectious Diseases.

Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU

M. Hackel, M. Motyl, P. Moise, 2021, JAC-antimicrobial resistance.

Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United States

M. Motyl, E. Wenzler, K. Bauer, 2022, Antibiotics.

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.

M. Motyl, J. Karlowsky, D. Sahm, 2023, International Journal of Antimicrobial Agents.